Novo Nordisk Net Worth 2010-2022 | NVO

Interactive chart of historical net worth (market cap) for Novo Nordisk (NVO) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Novo Nordisk net worth as of January 27, 2023 is $311.25B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $311.249B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $441.560B 16.62
Eli Lilly (LLY) United States $330.671B 41.73
Merck (MRK) United States $270.958B 13.95
AbbVie (ABBV) United States $260.674B 10.81
Pfizer (PFE) United States $248.389B 6.79
Novartis AG (NVS) Switzerland $198.780B 14.97